Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice

Arun Lakshmanan, Rajarajan A. Thandavarayan, Kenichi Watanabe, Flori R. Sari, Harima Meilei, Vijayasree V. Giridharan, Vijayakumar Sukumaran, Vivian Soetikno, Somasundaram Arumugam, Kenji Suzuki, Makoto Kodama

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

There is increasing evidence that angiotensin (Ang)-II plays an unprecedented role in diabetic complications. It could also be an important therapeutic target for ameliorating various diseases, especially diabetic nephropathy (DN). We therefore studied the beneficial effects of olmesartan, an Ang-II type 1 receptor (AT-1R) blocker in streptozotocin (150. mg/kg, BW)-induced diabetic kidney disease in mice. The diabetic kidney mice displayed upregulated protein expression levels of AT-1R, AT-2R, ERK-1/2, p-p38 MAPK, p-MAPKAPK-2, ET-1, p-JNK, p-c-Jun, TGF-β1, and gp91-phox, and all of these effects were expectedly downregulated by an olmesartan treatment. Also, immunohistochemical analysis, and Azan-Mallory and HE staining were performed to examine the expression of collagen-III and fibronectin, renal fibrosis, and hypertrophy, respectively. Furthermore, olmesartan treatment significantly abrogated the downregulation of ACE-2 and Ang-(1-7) mas R protein expression in diabetic kidney mice. Considering all these findings together, the AT-1R/MAPK pathway might be a potential therapeutic target in diabetes kidney disease, and olmesartan treatment could have beneficial effects on DN by modulating the AT-1R/MAPK pathway.

Original languageEnglish
Pages (from-to)104-111
Number of pages8
JournalMolecular and Cellular Endocrinology
Volume348
Issue number1
DOIs
Publication statusPublished - 2 Jan 2012
Externally publishedYes

Fingerprint

Diabetic Nephropathies
Streptozocin
Modulation
Kidney
Down-Regulation
Angiotensin II Type 1 Receptor Blockers
Kidney Diseases
p38 Mitogen-Activated Protein Kinases
Diabetes Complications
Medical problems
Fibronectins
Angiotensin II
Hypertrophy
Proteins
Fibrosis
Collagen
Staining and Labeling
olmesartan
Therapeutics

Keywords

  • AT-1R/MAPK pathway
  • Diabetic nephropathy
  • Olmesartan

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Biochemistry

Cite this

Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. / Lakshmanan, Arun; Thandavarayan, Rajarajan A.; Watanabe, Kenichi; Sari, Flori R.; Meilei, Harima; Giridharan, Vijayasree V.; Sukumaran, Vijayakumar; Soetikno, Vivian; Arumugam, Somasundaram; Suzuki, Kenji; Kodama, Makoto.

In: Molecular and Cellular Endocrinology, Vol. 348, No. 1, 02.01.2012, p. 104-111.

Research output: Contribution to journalArticle

Lakshmanan, A, Thandavarayan, RA, Watanabe, K, Sari, FR, Meilei, H, Giridharan, VV, Sukumaran, V, Soetikno, V, Arumugam, S, Suzuki, K & Kodama, M 2012, 'Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice', Molecular and Cellular Endocrinology, vol. 348, no. 1, pp. 104-111. https://doi.org/10.1016/j.mce.2011.07.041
Lakshmanan, Arun ; Thandavarayan, Rajarajan A. ; Watanabe, Kenichi ; Sari, Flori R. ; Meilei, Harima ; Giridharan, Vijayasree V. ; Sukumaran, Vijayakumar ; Soetikno, Vivian ; Arumugam, Somasundaram ; Suzuki, Kenji ; Kodama, Makoto. / Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. In: Molecular and Cellular Endocrinology. 2012 ; Vol. 348, No. 1. pp. 104-111.
@article{99cc5762d6c545bf9010066ad94b7d6d,
title = "Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice",
abstract = "There is increasing evidence that angiotensin (Ang)-II plays an unprecedented role in diabetic complications. It could also be an important therapeutic target for ameliorating various diseases, especially diabetic nephropathy (DN). We therefore studied the beneficial effects of olmesartan, an Ang-II type 1 receptor (AT-1R) blocker in streptozotocin (150. mg/kg, BW)-induced diabetic kidney disease in mice. The diabetic kidney mice displayed upregulated protein expression levels of AT-1R, AT-2R, ERK-1/2, p-p38 MAPK, p-MAPKAPK-2, ET-1, p-JNK, p-c-Jun, TGF-β1, and gp91-phox, and all of these effects were expectedly downregulated by an olmesartan treatment. Also, immunohistochemical analysis, and Azan-Mallory and HE staining were performed to examine the expression of collagen-III and fibronectin, renal fibrosis, and hypertrophy, respectively. Furthermore, olmesartan treatment significantly abrogated the downregulation of ACE-2 and Ang-(1-7) mas R protein expression in diabetic kidney mice. Considering all these findings together, the AT-1R/MAPK pathway might be a potential therapeutic target in diabetes kidney disease, and olmesartan treatment could have beneficial effects on DN by modulating the AT-1R/MAPK pathway.",
keywords = "AT-1R/MAPK pathway, Diabetic nephropathy, Olmesartan",
author = "Arun Lakshmanan and Thandavarayan, {Rajarajan A.} and Kenichi Watanabe and Sari, {Flori R.} and Harima Meilei and Giridharan, {Vijayasree V.} and Vijayakumar Sukumaran and Vivian Soetikno and Somasundaram Arumugam and Kenji Suzuki and Makoto Kodama",
year = "2012",
month = "1",
day = "2",
doi = "10.1016/j.mce.2011.07.041",
language = "English",
volume = "348",
pages = "104--111",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice

AU - Lakshmanan, Arun

AU - Thandavarayan, Rajarajan A.

AU - Watanabe, Kenichi

AU - Sari, Flori R.

AU - Meilei, Harima

AU - Giridharan, Vijayasree V.

AU - Sukumaran, Vijayakumar

AU - Soetikno, Vivian

AU - Arumugam, Somasundaram

AU - Suzuki, Kenji

AU - Kodama, Makoto

PY - 2012/1/2

Y1 - 2012/1/2

N2 - There is increasing evidence that angiotensin (Ang)-II plays an unprecedented role in diabetic complications. It could also be an important therapeutic target for ameliorating various diseases, especially diabetic nephropathy (DN). We therefore studied the beneficial effects of olmesartan, an Ang-II type 1 receptor (AT-1R) blocker in streptozotocin (150. mg/kg, BW)-induced diabetic kidney disease in mice. The diabetic kidney mice displayed upregulated protein expression levels of AT-1R, AT-2R, ERK-1/2, p-p38 MAPK, p-MAPKAPK-2, ET-1, p-JNK, p-c-Jun, TGF-β1, and gp91-phox, and all of these effects were expectedly downregulated by an olmesartan treatment. Also, immunohistochemical analysis, and Azan-Mallory and HE staining were performed to examine the expression of collagen-III and fibronectin, renal fibrosis, and hypertrophy, respectively. Furthermore, olmesartan treatment significantly abrogated the downregulation of ACE-2 and Ang-(1-7) mas R protein expression in diabetic kidney mice. Considering all these findings together, the AT-1R/MAPK pathway might be a potential therapeutic target in diabetes kidney disease, and olmesartan treatment could have beneficial effects on DN by modulating the AT-1R/MAPK pathway.

AB - There is increasing evidence that angiotensin (Ang)-II plays an unprecedented role in diabetic complications. It could also be an important therapeutic target for ameliorating various diseases, especially diabetic nephropathy (DN). We therefore studied the beneficial effects of olmesartan, an Ang-II type 1 receptor (AT-1R) blocker in streptozotocin (150. mg/kg, BW)-induced diabetic kidney disease in mice. The diabetic kidney mice displayed upregulated protein expression levels of AT-1R, AT-2R, ERK-1/2, p-p38 MAPK, p-MAPKAPK-2, ET-1, p-JNK, p-c-Jun, TGF-β1, and gp91-phox, and all of these effects were expectedly downregulated by an olmesartan treatment. Also, immunohistochemical analysis, and Azan-Mallory and HE staining were performed to examine the expression of collagen-III and fibronectin, renal fibrosis, and hypertrophy, respectively. Furthermore, olmesartan treatment significantly abrogated the downregulation of ACE-2 and Ang-(1-7) mas R protein expression in diabetic kidney mice. Considering all these findings together, the AT-1R/MAPK pathway might be a potential therapeutic target in diabetes kidney disease, and olmesartan treatment could have beneficial effects on DN by modulating the AT-1R/MAPK pathway.

KW - AT-1R/MAPK pathway

KW - Diabetic nephropathy

KW - Olmesartan

UR - http://www.scopus.com/inward/record.url?scp=80755172244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755172244&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2011.07.041

DO - 10.1016/j.mce.2011.07.041

M3 - Article

VL - 348

SP - 104

EP - 111

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1

ER -